Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1

Garcia-Contreras F, Nevarez-Sida A, Constantino-Casas P, Abud-Bastida F, Garduno-Espinosa J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
16740439

DOI
10.1016/j.arcmed.2005.11.010

Indexing Status
Subject indexing assigned by NLM

MeSH
Adjuvants, Immunologic /economics /therapeutic use; Antiviral Agents /economics /therapeutic use; Costs and Cost Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic /complications /drug therapy /economics /epidemiology; Humans; Interferon-alpha /economics /therapeutic use; Liver Cirrhosis /epidemiology /etiology; Male; Mexico; Polyethylene Glycols /economics /therapeutic use; Prospective Studies; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin /economics /therapeutic use; Thymosin /analogs & derivatives /economics /therapeutic use

AccessionNumber
22006001210

Date bibliographic record published
06/07/2006